European ophthalmologists debate

Article

European Ophthalmology, the social networking group for European ophthalmologists created and moderated by Ophthalmology Times Europe, has recently launched its new discussion forum.

European Ophthalmology, the social networking group for European ophthalmologists created and moderated by Ophthalmology Times Europe, has recently launched its new discussion forum.

We at Ophthalmology Times Europe want to know what you think on a variety of issues that impact directly on your community. A selection of the discussion comments posted will be published in a new feature in the magazine, starting next month. As the voice of the European ophthalmology community, we’d like to represent your views accurately, so your comments will be completely free from censorship: please feel free to discuss your opinions at will.

European Ophthalmology and Ophthalmology Times Europe have no material interest in these discussions: we merely wish to stimulate debate within the industry, and find out how you feel about issues affecting your industry, so that we can accurately represent and respond to your needs.

To become a member of our online community, please go to www.oteurope.com/forum. If you are already a member, please go to www.oteurope.com/discuss to start your own or join in with any of our current discussions.

In conjunction with the debates that we are running, we are also conducting a series of brief surveys (right), so even if your time is limited, you can still make your opinion count, simply at the touch of a button.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.